However, the impact of TP53 mutations on clinical outcomes in NSCLC patients with EGFR-mutation treated with first-line TKIs requires further elucidation (36), and the molecular mechanism among them remains largely unknown. This evidence concerns the gene TP53 and non-small cell lung carcinoma.